Johnson & Johnson completed the acquisition of Abiomed for $16.6bn.

Johnson & Johnson, a health care company, completed the acquisition of Abiomed, a provider of medical technology that provides circulatory support and oxygenation, for $16.6bn. “The addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech. We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders,” Joaquin Duato, Johnson & Johnson CEO.